•
Dec 31, 2021

Akoya Q4 2021 Earnings Report

Akoya reported a record quarterly revenue and grew its installed base.

Key Takeaways

Akoya Biosciences reported a strong finish to 2021 with record quarterly revenue of $16.2 million, representing a 26% increase compared to the prior year period. The company's installed base grew to nearly 700 instruments worldwide, and there are approximately 500 publications on Akoya platforms to date. The commercial launch of the PhenoCyclerâ„¢-Fusion System was a highlight of the quarter.

Total revenue was $16.2 million, a 26% increase compared to the prior year period.

Product revenue was $12.9 million, a 23% increase compared to the prior year period.

Services and other revenue totaled $3.2 million, a 33% increase compared to the prior year period.

Gross profit was $10.2 million, a 29% increase compared to the prior year period, with a gross profit margin of 63.3%.

Total Revenue
$16.2M
Previous year: $12.9M
+25.2%
EPS
-$0.47
Previous year: $2.49
-118.9%
Gross Profit
$10.2M
Previous year: $7.91M
+29.3%
Cash and Equivalents
$113M
Previous year: $17M
+564.9%
Free Cash Flow
-$7.22M
Previous year: -$2.63M
+174.1%
Total Assets
$191M
Previous year: $77.7M
+145.8%

Akoya

Akoya

Akoya Revenue by Segment

Revenue & Expenses

Visualization of income flow from segment revenue to net income